Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
About the slate of nominees for the BOD Posted last night on Facebook by Russ Rosenbaum, son of the Spokesman for the 13D Group "Thank you to everyone who has reached out to me via private message. I'm glad to know how many of you are interested to hear what my Dad has to say. My Dad has always taught us that you you get one chance to make a good impression. There is a lot of work being put into the initial roll-out that includes the announcement of the slate for the board and the letter that starts their campaign. I know you will be impressed. I can tell you that the announcement will be released no later than Friday July 2nd. I don't have any further information to share at this time but I do read the board and will be able to interact more after the announcement has been made. I wish you all a good night".
The 5% Poster is expressing his opinion, not fact. If there is a contested election and there might not be, only the top five with the most votes will be seated on the BOD. It is possible, a mix of old and new Directors will win. So, 5% can't be certain how any individual candidate will do. We are all anxious to learn if there is going to be a contested election and, if so, who will be the candidates and the "platform" for moving LL to approval. Your vote matters.
Misiu, if there is a Proxy Contest, every candidate will want your vote. You will be able to choose between existing individual Directors and any others who are nominated. Every vote counts and every shareholder who owns shares benefits according to the number of shares they own. Large and small alike are all in the same boat.
I suspect if an alternative slate for election to the BOD is presented, each Director Nominee will share their credentials and intentions. If there is a "Comprehensive Plan" which shareholders like better than what is offered by the Company's nominees, the alternative nominees have a decent chance of winning. If the plan is suspect, they will have no chance of prevailing. Bottom line, shareholders will have to be well informed, if there is to be a competitive election process. But I must say, I hate waiting to learn more...
Whats done is done,let's move on. Hopefully, we will have a choice to vote for new Directors committed to resetting the pathway to approval for Leronlimab.
No BK because the company's IP is not collateral for any debt, so no advantage for creditors to push company to the brink. Also, the inventory is controlled by Samsung and other suppliers, so unavailable and worthless to any unsecured creditor. IMO, should there be a proxy contest and new Directors are chosen, available "go forward" funding will be forthcoming. For sure, the next few months will determine the fate of this company.
I assume you are referring to the Judge's Opinion released last week. Below is the link:
https://www.dropbox.com/s/nie8nks2ev0azlu/Judge%20Oral%20Decision%20%2800223760xCDE20%29%20%281%29.pdf?dl=0
Here is a link to the 41 page Judge's Opinion released last week.
Whether a supporter or critic of CYDY management, you should be concerned, to say the least.
https://drive.google.com/file/d/1CI3RXbJtpNkkI5H2kRTlZjS_6cBOiCLA/view
Beginning on Page 28 Line 5 is particularly disturbing.
Plaintiffs saved us many more millions of dollars even after the legal fees are paid, which should be paid by the Directors who failed to uphold their fiduciary responsibilities to Cytodyn shareholders.
The CEO and the Directors who went along with the scheme should pay the legal fees individually, not the Company. After all, they were the ones who stood to benefit, so its only right that they are liable and accountable for the cost of their failure. Two of the Directors were not directly complicit IMO and they eventually conducted a thorough and fair investigation into the matter.
Yes, they are listed shareholders in the 13D, but neither they, nor anyone else has been nominated for the BOD.
You are making a lot of assumptions which may not be accurate regarding potential changes. Why not wait for more information before deciding one way or the other? If and when there are actual candidates to choose from, we can assess their qualifications and vote accordingly.
Misiu, Mr. Rosenbaum son posted this on Facebook, maybe this will ease your worry a bit.
" ...I am invested in CYDY and a long as well. Here is what I can tell you. My father is doing this for all the right reasons. My father is passionate about the success of the company and the product. There will be lots of information coming out soon. But any rumor that questions whether the intent is anything but to make Cytodyn a successful long-term company and investment and bring Leronlimab to all patients who need it are false. My father only wants to see Cytodyn be the best it can be..."
Let's keep an open mind, there are different pathways to "Approval" and advancing LL for the benefit of patients and shareholders.
Though sometimes disappointed, I always like to think the best of people.
As a shareholder since 2015, I understand the frustration of waiting so long for LL to be recognized as the world class medication it is. More importantly, it is heart breaking to know that so many people could have been helped and weren't because LL was not available to them. We need to enlist the help of those who can facilitate positive change and hopefully we shareholders will play a constructive role in the process.
As I see the situation:
1. CYDY management is largely incompetent and blew the CD12 Trial Design.
2. That said, shareholders should review the public statements and research of Dr. Bruce Patterson. Dr. Patterson is a brilliant Virologist and, in spite of being poorly treated by Cytodyn, is a proponent of the validity of the science underlying LL MOA. I have heard him state and extol the drug's remarkable efficacy and potential.
3. So, regardless of current management's mishandling of a truly amazing opportunity, I believe that eventually the BOD, to secure regulatory approval, will have to bring in new management and/or secure an association with a strong biopharma company.
4. My perspective is based on six years as a shareholder and intense DD, as well as personal communication with some of the principal players. Still, IMHO CYDY is a reasonably good long term investment.
Today's Zack Report is an excellent analysis and review of the potential appreciation of SNGX.
Enjoy?
https://s1.q4cdn.com/460208960/files/News/2020/Zacks_SCR_Research_11162020_SNGX_Bautz.pdf
Proven efficacy and safety Phase 3 hit endpoints should result in fast track approval once BLA is submitted. SNGX appears to be extremely undervalued by the market.
Massimo Cristofanilli, the lead researcher listed in the Abstract is solid validation that Leronlimab is a real possible game changer when it comes to mTNBC. A google search will tell you all you need to know about him.
mTNBC Abstract just published
https://cancerres.aacrjournals.org/content/80/16_Supplement/CT233
Conclusion: "Conclusions: Leronlimab (PRO 140), a CCR5 antagonist mAb, in combination with carboplatin is currently enrolling newly diagnosed mTNBC. The preliminary analysis shows safety and tolerability of the combination and continue to enroll patients with initial promising clinical activity, potentially suggesting the future availability of a new effective agent in the management of this serious condition."
SNGX looks to be a solid company with a promising pipeline, but has been overlooked by BioTech investors, so it is amazing to see this morning's massive volume.
Soligenix Announces Publication of Positive Pre-clinical Results for a Novel COVID-19 Vaccine
This is a "heat stable" CoVaccine HT(TM) Adjuvant in a Prototype Vaccine. It has huge advantages over current vaccine candidates.
While a bit late to the Covid fight, the Soligenix approach has ramifications for a broad range of applications.
After listening to the oral arguments, I don't believe there is enough information to determine which way the Appeal will go.
Link to new article sent via email by NP a few minutes ago. A must read.
https://insiderfinancial.com/investors-fleeing-cytodyn-missing-the-golden-nugget-from-the-bla-delay-could-risk-serious-upside-coronavirus-potential/179575/
This is confirmation of previous results as well as new information. This is critical because CAML cells have been found to impact "Overall Survival" (OS). The PR clearly states that
“Other cancer-associated macrophage-like (CAML) cells in the blood sample were found at the lower limits of detection and were also decreased in size. Most importantly, the CAML cells had reduced CCR5 staining compared to samples taken from the patient three weeks earlier, reflecting an ongoing blockade of the CCR5 receptor by leronlimab.”
IMHO, this is just as important as the suppression of CTC in controlling metastasis.
LifeSci PR is a topnotch firm. If you drill down on their website, you will be impressed.
OHM20, I agree , 100% against using the IP as Collateral for a loan. A non-recourse instrument would be okay, but no lender will offer significant funds without the keys to the vault, which is the IP. It's just not worth the risk. Given the potential value of CYDY, more dilution is better than an IP collateralized debt.
If I were hosting a CC with solid positive news, I would hold it on a Monday.
Is this opinion or inside information?
NP stated they will accept one of the agreements. Implication is that upfront payment, terms, and conditions are acceptable. Likely involves Combo and/or another indication, maybe colon cancer, as this was unclear to me. Thoughts?
It is the BOD call, as to whether or not or for how much to sell the company. NP is but one vote and does not represent a significant shareholder block, as do several of the other Directors. NP's job is to execute and is not strategic. It is debatable as to how well he has executed and depends on whether one sees a "glass half full or half empty".
Yes, IMO, it is extremely important in our cancer studies to know which patients express high CCR5 density.
Predicting which patients will benefit from CCR5 inhibiting drugs is huge. IMO, the implications for Cytodyn of this discovery are incalculable. It is beyond my knowledge to comment further, perhaps others could post on how physicians will utilize the assay results in planning treatment. Obviously, selecting CCR5 dense clinical trial patients in Cytodyn's studies will significantly improve patient response and efficacy.
Samsung doesn't dabble in markets, they own them. Expect there is a development plan and it appears Leronlimab could play an integral role.
Samsung Biologics equity investment is one possibility.
MrGuru, I think many of us agree with your perspective and invested in Cytodyn thinking a BO was in the near term. Now, not so much.
BTW, thank you for posting the background on the competitive landscape for HIV. drugs.
And what's the deal with Syneos Health. Syneos is a multi billion dollar firm with top drawer talent. If they are openly talking about them, we must be close to a deal with them IMO.
If reports from Shareholder Meeting are accurate, I would think a PR will need to be released today or tomorrow.
Appreciate your sharing your reasons, commitment, and beliefs for putting your money on CYDY. If the majority of warrant holders share your views, the company will be in great shape. Thank you.
FDA note:
"The actual start date on which the first participant was enrolled in a clinical study." April 22, 2019, hard to believe that is an error, we'll find out soon.